Form 4 for AVTR Avantor, Inc.
Accepted 2022-01-05 00:00:00 ET · period of report 2022-01-02 · accession 0001722482-22-000011 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2022-01-05 | 2022-01-02 | AVTR | Brophy Gerard | EVP, Biopharma Production | F - Tax | $42.14 | -6,516 | 142.9K | -4% | -$274.6K |
| DM | 2022-01-05 | 2022-01-03+ | AVTR | Brophy Gerard | EVP, Biopharma Production | S - Sale+OE | $40.42 | -71.0K | 142.9K | -33% | -$2.87M |
| D | 2022-01-05 | 2022-01-03 | AVTR | Brophy Gerard | EVP, Biopharma Production | M - OptEx | $18.45 | +59.4K | 202.3K | +42% | +$1.10M |
| D | 2022-01-05 | 2022-01-03 | AVTR | Brophy Gerard | EVP, Biopharma Production | M - OptEx | $0.00 | -59.4K | 59.4K | -50% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2022-01-02 | F | D | 6,516 | $42.14 | 142,863 | D | — | — | |
| 2 | Common | Common Stock | 2022-01-05 | S | D | 11,551 | $38.65 | 131,312 | D | — | — | (F4) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $38.44 to $38.87, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. |
| 3 | Common | Common Stock | 2022-01-03 | S | D | 59,418 | $40.77 | 142,863 | D | — | — | (F3) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions ranging from $40.27 to $41.97, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth above. |
| 4 | Common | Common Stock | 2022-01-03 | M | A | 59,418 | $18.45 | 202,281 | D | — | — | |
| 5 | Derivative | Stock Options (Right to Buy) | 2022-01-03 | M | D | 59,418 | $0.00 | 59,417 | D | $18.45 · — to 2030-01-02 | 59,418 Common Stock | (F5) Reflects an initial grant of 178,253 stock options that vest in three equal installments beginning on January 2, 2021. |